FDA Approved Eczema with Dupilumab

FDA Approved Dupilumab to Treat Eczema

Dupilumab (Dupixent) was approved by the FDA in 2017 to treat moderate to severe eczema (or atopic dermatitis).

“This medicine has been a game-changer for my patients, many of whom have been suffering most of their lives,” says Dr. George. Approximately 30% of children and 10% of adults suffer from eczema. Before this new treatment option, patients were stuck with messy topical steroids and higher risk systemic medicines to suppress the immune system which worked only moderately well for some or not at all. The skin clearance has been remarkable with Dupixent, giving patients hope that they can finally have relief from itchy, raw, red, cracked skin.

If you believe that you may be suffering from Eczema schedule your appointment today with Dr. Mary Noel George, a board certified dermatologist that can help you find the best treatment for you!

What Our Patients Are Saying

Dr Katherine M. Moritz is the bomb-diggity!!! She’s very professional, kind, and most of all caring for my concerns and needs. Today, I walked out of her office with my son in my arms in tears of joy. She removed a cyst on my eyelid that had been there for over a year now. In a matter of seconds, she painlessly had it removed. When I looked in the bathroom mirror, I ran back into her office thanking the staff and giving her my gratitude and thanks. I swear, I cried when I got into my car all over again. This place is a whole vibe, they are culturally competent, and she’s helping me live my wishes in my 40’s, that I had in high school. Dr. Moritz is like the fountain of youth, she’s reversing my aging and I feel more confident in myself than I did in my 20’s.

San Juan
See More Reviews

Request An Appointment

Contact our office by filling out the form or calling the number below to speak with a member of our team to schedule an appointment.

(314) 344-0004








    *All fields required. Do not submit medical or personal messages on this form. Any personal or medical questions should be submitted by telephone (314) 344-0004.